73 related articles for article (PubMed ID: 21258186)
1. [Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib].
Matsumura I; Nannya Y; Nagai T; Tanimoto K; Fujikawa K; Kasai M; Inaguma Y; Takeuchi M; Niimi H; Kashiwagi H; Imamura Y; Yagi T; Sakamoto E; Okabe M; Aoki G; Katayama T; Okada M; Adachi Y; Saburi Y; Kizaki M
Rinsho Ketsueki; 2010 Dec; 51(12):1762-8. PubMed ID: 21258186
[TBL] [Abstract][Full Text] [Related]
2. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
3. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
4. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
6. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
10. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
11. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
12. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
14. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.
Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K
Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
17. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
18. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
19. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
